Drug Combination Details
| General Information of the Combination (ID: C90907) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Bacillus Calmette-Guerin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MBT-2 | CVCL_4660 | Bladder transitional cell carcinoma | Mus musculus | ||
| 253J-BV | CVCL_7937 | Bladder carcinoma | Homo sapiens | |||
| KU-7 | CVCL_4714 | Bladder cancer | Homo sapiens | |||
| RT4v6 | CVCL_T027 | Bladder carcinoma | Homo sapiens | |||
| In-vivo Model | Animal models were constructed by subcutaneously injecting MBT-2 cells into both flanks of C3H female mice. | |||||
| Experimental
Result(s) |
Curcumin potentiates the antitumor effect of BCG through the inhibition of NF-kappaB and induction of TRAIL receptors in bladder cancer cells. | |||||
